Qiagen

Companies Qiagen

News Qiagen

• Drug Response Dx concludes first round of financing with support from QIAGEN and High-Tech Gründerfonds

  Drug Response Dx GmbH (DRDx GmbH) concluded its first round of financing with High-Tech Gründerfonds and QIAGEN. The investment will serve to develop a biomarker test kit for rheumatoid arthritis treatment guidance with so-called TNF-alpha inhibitors. The test is secured by a patent platform exclusi more

• QIAGEN and Bayer HealthCare partner to develop companion diagnostics to guide treatment decisions for targeted cancer therapies

  QIAGEN and Bayer HealthCare announced a collaboration agreement for the development and commercialization of companion diagnostics paired with novel Bayer HealthCare drugs, initially to enhance the treatment of various solid tumors. Companion diagnostics are tests that unlock molecular information f more

• QIAGEN achieves Personalized Healthcare milestone with U.S. approval of companion diagnostic for colorectal cancer

  QIAGEN N.V.  announced it has received U.S. Food and Drug Administration (FDA) approval to market the therascreen® KRAS RGQ PCR Kit (therascreen KRAS test) to provide guidance on the use of Erbitux® (cetuximab) as a treatment in patients with metastatic colorectal cancer. The U.S. FDA approval of th more

White papers Qiagen

• LightCycler® 480 System: High-throughput Gene Expression and Genotyping Analysis - A Performance Study
  

  The LightCycler® 480 System is a novel platform for rapid gene expression and melting curve-based genotyping for medium- and high-throughput. In order to assess the performance and ease-of-use of the complete LightCycler® 480 System (instrument, software, and reagents) in an academic laboratory setting we scheduled a high-throughput project including gene expression (39 targets in 88 samples = 3,400 expression values) as well as genotyping applications (3,808 genotypes; 14 SNPs in 288 samples). The project, involving five technicians and two graduate students, was accomplished within 15 working days. more

• LOOXSTER® concentrates bacterial DNA
  

  Detection of the bacterial content of a specific sample, irrelevant from its source, is not as straightforward as it seems. In clinical microbiology laboratories, the gold standard method for the detection of pathogens in patients suspected of systemic infections is the blood culture. However, this technique is known to have many drawbacks especially with regard to patient's antibiotics treatment, low abundance and non-cultivable organisms. Moreover, it takes usually 3 to 5 days to obtain a result from blood culture which is too late to initiate proper antibiotic therapy. Amplification-based methods such as PCR allow results in a more rapid fashion. However, their sensitivity, to date, are no better, and sometimes worse, than culture-based methods. more

Publications Qiagen

• Combination of Pyrosequencing® and Sanger sequencing reveals alleged novel mutation in exon 18 of EGFR

  Background:EGFR sequencing is crucial for therapeutic decisions in treatment regimens of lung cancer patients. Several mutations have been identified in the past, of which some were confirmed as activating or resistance mutations by in vitro phenotyping. In this study, novel mutations of so far unkn more

• Assessment of Two Immunodepletion Methods: Off-Target Effects and Variations in Immunodepletion Efficiency May Confound Plasma Proteomics

  Immunodepletion of abundant plasma proteins increases the depth of proteome penetration by mass spectrometry. However, the nature and extent of immunodepletion and the effect of off-target depletion on the quantitative comparison of the residual proteins have not been critically addressed. We perfor more

• Genetic characterization of bovine viral diarrhoea (BVD) viruses: confirmation of the presence of BVD genotype 2 in Africa

  Bovine viral diarrhoea virus (BVDV) has emerged as one of the economically important pathogens in cattle populations, with a worldwide distribution and causing a complex of disease syndromes. Two genotypes, BVDV 1 and 2, exist and are discriminated on the basis of the sequence of the 5′ non-coding r more

Market studies Qiagen

• Global Molecular Diagnostics Market Report: 2012 Edition

  Human being has evolved with an unending quest for exploration. With constant research in medical and other sciences, molecular diagnostic tools and techniques were developed. Besides providing the medical work and a wider spectrum and accuracy of test findings, these tests have also enabled researc more

• Brazil In Vitro Diagnostics Market Outlook to 2017 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microb ...

  Introduction GlobalData’s new report, “Brazil In Vitro Diagnostics Market Outlook to 2017 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture” provides key market data on the Brazil In Vitro Diagnostics market. more

• Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017

  Introduction ”Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017”, a new report by Global Markets Direct, provides key market data on the Greece In Vitro Diagnostics market. The report provides value (USD million), for each segment and sub-segment within seven mark more

Websites Qiagen